Cost-Effective, Safe, Cardiac Function Technology Featured
At MDI's Annual Emerging Medical Technologies East Conference
IRVING, Texas, Sept. 15 /PRNewswire/ -- 2000 Emerging Medical Technologies
(EMT) East Conference-"Optimization" is becoming a new buzzword among health
care practitioners. Various research -- conducted both here and abroad -- has
shown that keeping fluid levels at their best in critical care patients leads
to fewer deaths, lesser complications and reduced hospital stays -- the latter
of which can easily translate to lower healthcare costs. UK-based Deltex
Medical (EASDAQ: DLTX) finds itself poised to further this burgeoning
optimization movement. Multiple outcome studies have been conducted with the
Company's technology and each has demonstrated more than a 30% reduction in
patient morbidity and subsequent length of hospital stay.
Deltex Medical's CardioQ(TM) will be the featured topic of CEO and
President Kemp Coady's presentation on September 19 at the EMT East
Conference. The CardioQ is a continuous, non-invasive cardiac function and
volume status monitor that allows early diagnosis of changes in patients'
cardiac condition and provides immediate feedback on the effects of
therapeutic interventions. It provides doctors with 'beat-to-beat'
information on how efficiently the heart is transporting oxygen-carrying blood
to the body's organs and how well patient fluid levels are being maintained.
The amount of fluid within a patient is critical to his or her physical
well being as low volume in the circulatory system can lead to poor oxygen
delivery throughout the body. This lack of adequate fluid, called covert
hypovolemia, is recognized as one of the key risk factors associated with
complications surrounding surgery.
"The consistent benefits associated with patient fluid optimization,
regardless of which methodology is used to achieve it, appears to be
furthering our presence in the operating room, intensive care unit and
emergency department," reports Coady. "The real-time responsiveness of
harmless Doppler-derived information to determine adequate oxygen delivery may
very well make the Deltex Medical approach the 'optimal' choice among health
care professionals."
The Company estimates a market potential of more than 6 million CardioQ
cases per year. Deltex Medical is based in Chichester, West Sussex, UK, and
has an office in Dallas, TX.
SOURCE Deltex Medical
 back to top
Related links:
http://www.deltex.com
CONTACT:
Kempton J. Coady, III, President and CEO of
Deltex Medical, 203-454-1675; or Deltex Medical, 972-929-1049
|
